Our investment approach
IGC invests in established companies seeking resources to support high levels of growth. We work collaboratively with management teams and earlier investors to complement their experience at the board level and bring later-stage venture expertise.
IGC investments can range from $5 million to $30 million. We typically lead investments in companies seeking to build upon an existing investor syndicate and in bootstrapped companies that are ready to diversify their ownership.
We primarily invest in preferred equity of private companies, but we have significant flexibility and experience in investing in public companies and in secondary transactions. IGC works with a broad network of investment banking, legal and consulting firms that serve the venture community.
IGC’s Healthcare Team invests in differentiated products and services that deliver meaningful clinical and economic benefits over the standard of care.
Our primary investment focus is on specialty pharmaceuticals, biopharmaceuticals and medical devices. Our team has significant experience investing in products with demonstrated evidence of clinical efficacy, providing growth capital to early commercial-stage companies, and financing acquisitions for companies with marketed products. We selectively invest in opportunities where earlier human clinical data can drive value inflection.
We have invested in and are increasingly exploring opportunities in healthcare information technology and diagnostics as these become more integrated into therapeutic management and the delivery of care.
Examples of typical investments include:
- Funding a later-stage clinical development candidate through regulatory clearance
- Providing growth capital for a company to accelerate commercialization
- Financing a commercial-stage company’s acquisition of a new product to drive operating leverage
- Investing in public companies with assets that are undervalued or misunderstood by the market
- Purchasing a secondary position from an early shareholder in conjunction with primary capital infusion into the company
IGC’s Information Technology Team invests in information technology companies that have a completed product or service offering with demonstrated market demand. Typically, our capital is deployed to accelerate already visible business momentum – usually through increased investment in sales and marketing, an expanded product offering or the acquisition of complementary businesses.
Our target markets of interest include:
- Software with an emphasis on SaaS business models
- Technology-enabled services
- Datacenter technologies
- Tele/datacom equipment
- Internet services
- Clean tech
Case Studiesview all
Aptalis Pharma is a leading specialty pharmaceutical company providing innovative therapies for unmet medical needs, including gastrointestinal disorders and cystic fibrosis.Read The Case Study
BlueArc is a provider of scalable, high performance, network storage systems for the enterprise and data intensive markets, such as electronic discovery, entertainment, internet services and life sciences.Read The Case Study
Being one of the largest late-stage venture funds, you might think it would be hard to get their attention, but they are very focused.”